The global oxygen therapy market size was valued at USD 20.15 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 34.37 Billion by 2033, exhibiting a CAGR of 6.05% from 2025-2033. North America currently dominates the market, holding a market share of over 37.9% in 2024. The market in the region is primarily driven by the high prevalence of respiratory diseases, advancements in healthcare infrastructure, and increasing demand for home-based care solutions.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 20.15 Billion |
Market Forecast in 2033
|
USD 34.37 Billion |
Market Growth Rate 2025-2033 | 6.05% |
The oxygen therapy market is primarily driven by the increasing incidence of diseases such as chronic obstructive pulmonary disease (COPD) and asthma, which require long-term oxygen therapy. For instance, Emerson developed the ASCO™ Series 588 Stationary Oxygen Concentrator Manifold as a complete package for respiratory therapy layouts and to help expedite time to market. In addition, the enhanced portable oxygen devices give mobile support, which allows easy installation for in-home healthcare needs, aiding the market growth. Moreover, the percentage of the aging population group triggers respiratory illnesses more frequently, which is contributing to the market expansion. Besides this, the increased understanding of the benefits associated with oxygen therapy is boosting the use of oxygen across the globe, providing an impetus to the market. Apart from this, the continuous innovation in oxygen concentrators enhances the impact of treatment, thereby catalyzing the market growth.
The United States holds a share of 88.70% in the oxygen therapy market. The demand in the region is expanding, due to the increasing incidence of diseases of the respiratory system, especially COPD. Moreover, the increase in health care costs and insurance is driving the demand for oxygen therapies, supporting the market growth. Concurrently, continuous developments in home healthcare technology make it possible for patients to receive oxygen therapy at home, which is fueling the market demand. Also, higher public awareness of how respiratory health is valuable promotes early treatment, thus strengthening the market share. Apart from this, the government initiatives for chronic disease management increase oxygen prescription, as air pollution increases the burden of respiratory diseases, thereby propelling the market forward.
Home healthcare trends
Most patients especially the elderly and those with chronic diseases prefer to be treated at home instead of in hospitals or nursing homes. At-home care is often relatively cheaper as the devices are portable, and easy to manage, allowing the patient to maintain their mobility and freedom. The IMARC Group reports that the global home healthcare market reached USD 392.2 Billion in 2023. Most chronic respiratory conditions such as COPD and pulmonary fibrosis require oxygen therapy for the long term. Additionally, home healthcare is widely used as a tool for the management of all illnesses, aligning with the compliance of treatment regimens and impelling the market growth.
Increasing prevalence of respiratory diseases
According to an article published on the website of the World Health Organization (WHO) in 2023, the third leading cause of death worldwide is COPD, causing 3.23 million deaths in 2019. Oxygen therapy is extremely necessary during the treatment of symptoms of quite common diseases such as COPD, asthma, interstitial lung disease, or pneumonia. This is because respiratory ailments are injurious, and only extended treatment can help those patients, who have such conditions. Furthermore, oxygen therapy is of great importance in the prescription of sufficient oxygen in the blood for chronic respiratory illnesses, thus impelling market growth.
Aging population
The elderly patients suffer frequent respiratory conditions including COPD, emphysema as well as pneumonia, and the only known cure is the use of oxygen therapy. Respiratory diseases in old people may also be accompanied by other diseases such as hypertension, heart disease, and diabetes, which worsen respiratory diseases and therefore make oxygen therapy mandatory. Features characteristic of elders are the immune system that draws several infections leading to major respiratory illnesses. The elders also suffer from severe respiratory illnesses due to low immune system strength. An article published on the website of the International Monetary Fund (IMF) eLibrary shows that by 2050 the global share of people aged 80 and older is expected to quadruple to almost 5%.
IMARC Group provides an analysis of the key trends in each segment of the global oxygen therapy market, along with forecasts at the global, regional, and country levels from 2025-2033. The market has been categorized based on product, application, and end use.
Analysis by Product:
Oxygen source equipment stands as the largest component in 2024, holding around 57.6% of the market. It is essential for oxygen treatment because it supplies patients with the oxygen they require. Without these devices, it would be hard to provide oxygen to patients in need, making them market-essential. These devices are used in various contexts, including hospitals, clinics, and home healthcare facilities. Their adaptability and requirement in many healthcare settings are driving their strong adoption. Moreover, continuous advancements and improvements in oxygen source equipment, such as portable and lightweight designs, enhanced efficiency, and user-friendly features, are transforming the oxygen therapy market overview.
Analysis by Application:
Chronic obstructive pulmonary disease (COPD) leads the market with around 32.9% of the market share in 2024. The high incidence of COPD directly corresponds to a large patient population requiring oxygen therapy, making it the most common application area. COPD is a progressive and chronic ailment that usually worsens with time, and strongly demands long-term care procedures and treatment. Patients with COPD may require continuous or intermittent oxygen therapy to control symptoms and maintain their quality of life. Oxygen treatment alleviates respiratory difficulties and severe shortness of breath, making it an essential part of COPD management, thereby positively influencing the oxygen therapy market insights.
Analysis by End Use:
Home healthcare holds the largest market with around 32% of the market share in 2024. Many patients prefer to be treated at home rather than in hospitals or clinics for treatment. Home healthcare allows patients to continue their routines and stay in familiar environments, which benefits their overall well-being and satisfaction with the services. Additionally, home healthcare is more cost-effective than inpatient treatment in general. It eliminates long hospitalizations, reduces health costs, and relieves the burden on hospitals. This cost-saving is attractive to patients and healthcare providers. In portable oxygen concentrators and other home-use oxygen delivery systems, medical technology has made oxygen therapy more manageable for patients at home. Many of these gadgets have become easier to use, faster, and lightweight enhancing their application in the homes.
Analysis by Region:
In 2024, North America accounted for the largest market share of 37.9%. There is a high incidence of respiratory diseases in the region including COPD, asthma, and sleep apnea due to several factors including aging, smoking, and pollution. The availability of sophisticated technologies, easy access to these technologies, and robust reimbursement strategies all contribute to the growth of the market. In addition, the growth of home care and portable and easy-to-use oxygen therapy devices enhance the ability of patients to manage their diseases from their homes. Furthermore, important players in this area are interested in increasing the storage capacities of oxygen. For instance, in 2024 Chart Industries announced the grand opening of its jumbo cryogenic tank manufacturing facility in Theodore, Alabama.
The adoption of oxygen therapy is witnessing a notable rise, fueled by the increasing investments in healthcare systems. For instance, in 2024, US healthcare companies securing venture capital deals over USD 15 Million saw a surge in investments, benefiting oxygen therapy advancements. This growth enhances access to innovative treatments, improving patient care and outcomes. As healthcare expenditures continue to grow, there is a greater emphasis on improving patient care, particularly for those with respiratory disorders. Enhanced healthcare infrastructures and access to advanced treatments have led to a higher demand for therapies such as oxygen therapy. The growing awareness of respiratory diseases and their impact on quality of life further drives the demand for these treatments. As the need for specialized care expands, healthcare facilities are better equipped to administer oxygen therapy, making it more accessible to patients in need. The increase in research funding and technological advancements in oxygen delivery systems are also contributing to the rise in therapy adoption, offering more efficient and comfortable solutions for individuals with respiratory challenges.
Chronic diseases have been steadily rising, leading to an increasing need for oxygen therapy as a crucial part of patient management. The rising incidence of chronic conditions, such as COPD and heart diseases, requires long-term treatment, often involving oxygen support. The growing number of aging individuals, many of whom suffer from chronic ailments, has also played a significant role in the increased demand for oxygen therapy. For instance, in 2022, 2.9% of the EU population was aged 85 or older, with projections indicating this share will surpass 10% by 2050. This demographic shift highlights the increasing demand for oxygen therapy. Hospitals and medical care facilities are increasingly focusing on advanced therapies to support these patients. Moreover, the importance of oxygen therapy in improving their quality of life has been well recognized. New treatment protocols and greater access to home-based oxygen support devices further contribute to the widespread adoption of oxygen therapy. As healthcare institutions continue to prioritize the treatment of chronic conditions, the adoption of oxygen therapy has become a vital element in improving long-term patient outcomes, particularly for individuals with ongoing respiratory needs.
Asthma cases are on the rise across the region, leading to a surge in the adoption of oxygen therapy. For instance, asthma affects over 35 million people in India, contributing significantly to the growing number of asthma patients. Oxygen therapy offers a promising solution to alleviate symptoms and improve the quality of life for asthma patients. As asthma becomes more prevalent, patients need proper and constant therapy because of the rising frequency of the disease. This has led to an increased need for oxygen therapy which is fundamental in managing asthma by reducing the extent or destructiveness of the symptoms. Furthermore, treatments like oxygen therapy, and increased revenues are tied to the fact that the healthcare system in the region pays more attention to respiratory disorders as its foundation is being built up. As a result of development and innovations in the field of health, delivery systems for oxygen have improved and there is therefore increased capacity of the patient to be well cared for in both the hospital and at home. Enhancing the patient base, advanced treatment solutions, and enhancing consciousness levels regarding asthma management are contributing to the growth of oxygen therapy in the region.
With rising disposable income, more individuals in Latin America are seeking home healthcare solutions, including oxygen therapy. For instance, between 2021 and 2040, Latin America's total disposable income is projected to rise by nearly 60%, driven by regional disparities narrowing and technological advancements. This growth boosts demand for home healthcare services by enhancing affordability and accessibility. This economic growth is enabling a broader section of the population to afford at-home treatments for chronic respiratory conditions. The ability to manage health from the comfort of home is becoming more appealing, especially as the quality of healthcare services improves. Patients with respiratory illnesses prefer using client-transportable oxygen concentration equipment, which can be relocated in the home setting. Common hospital-based treatments are much more convenient and economical. The increased affordability of oxygen therapy as a home healthcare product along with easier access to healthcare products has played a vital part in the advancement of the therapy in the region. Rising disposable income is therefore central to the home health care oxygen therapy industry, thus driving the market forward.
Healthcare facilities in the region have expanded significantly, improving access to critical care and oxygen therapy services. According to the Dubai Healthcare City Authority report, by 2022, Dubai saw a significant expansion in healthcare facilities, with 4,482 private medical establishments, including 56 hospitals, and 55,208 licensed professionals. The Dubai Health Authority forecasts a 10-15% growth in medical professionals and a 3-6% rise in facilities through 2023 and beyond. The increased availability of medical centers and specialized healthcare providers has facilitated easier access to therapies for individuals with respiratory needs. With an emphasis on upgrading healthcare infrastructure, there has been a significant push to enhance treatment options, including oxygen therapy, for patients with respiratory disorders. The expansion of healthcare facilities ensures that more people can access essential services, such as oxygen therapy, which is vital for those suffering from chronic respiratory conditions. This development is creating a more favorable environment for the growth of oxygen therapy adoption across the region.
The global oxygen therapy market is highly saturated, and companies are striving to maintain their position through innovation of products, strategic partnerships, and new product launches. One of the major trends is the creation of portable and wearable oxygen delivery devices for meeting the growing home healthcare equipment market. Additionally, to enhance the efficiency, flexibility, and portability of a device, companies are increasingly underlining the significance of research and development (R&D). Other factors that are influencing the market include the approval of regulations for advanced technology and developing collaborations with the healthcare sector. Also, through acquisitions and mergers, competition is being pressed through market consolidation and improvements in product offerings. They point to the emergence of new respiratory ailments on the market and the shift towards home-based solutions.
The report provides a comprehensive analysis of the competitive landscape in the oxygen therapy market with detailed profiles of all major companies, including:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Oxygen Therapy Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Products Covered |
|
Applications Covered | Chronic Obstructive Pulmonary Disease, Asthma, Obstructive Sleep Apnea, Respiratory Distress Syndrome, Cystic Fibrosis, Pneumonia, Others |
End Uses Covered | Home Healthcare, Hospitals |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Allied Healthcare Products Inc., Becton Dickinson and Company, DeVilbiss Healthcare LLC (Drive Medical Inc.), Fisher & Paykel Healthcare Limited, General Electric Company, Getinge AB, Hersill SL, Invacare Corporation, Koninklijke Philips N.V, Smiths Group plc, Tecno-Gaz S.p.A., Teleflex Incorporated, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
The global oxygen therapy market was valued at USD 20.15 Billion in 2024.
IMARC Group estimates the market to reach USD 34.37 Billion by 2033, exhibiting a CAGR of 6.05% from 2025-2033.
Key factors driving the global oxygen therapy market include the rising prevalence of respiratory disorders like COPD and asthma, increasing geriatric populations, technological advancements in oxygen delivery systems, growing home healthcare trends, and heightened demand due to respiratory complications from environmental pollution.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, wherein North America currently dominates the global market.
Some of the major players in the global oxygen therapy market include Allied Healthcare Products Inc., Becton Dickinson and Company, DeVilbiss Healthcare LLC (Drive Medical Inc.), Fisher & Paykel Healthcare Limited, General Electric Company, Getinge AB, Hersill SL, Invacare Corporation, Koninklijke Philips N.V, Smiths Group plc, Tecno-Gaz S.p.A., Teleflex Incorporated, etc.